$MCK

Lerman Bradley E sold $269K of MCK

Lerman Bradley E sold 301 shares of MCKESSON CORP (MCK) at $892.32 ($0.27M total) on 2026-08-10.

Original reporting
SEC EDGAR · Lerman Bradley E
Published Aug 11, 2026, 6:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
low confidence
Mentioned
$MCK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may marginally influence sentiment, but it does not introduce new operational or financial guidance.

02

Market read

Traders may note the insider sale, but there is no fundamental catalyst in the text to drive a durable repricing.

03

What to watch

Insider sales often have limited predictive value without accompanying changes in guidance, contracts, or governance actions; also, the director’s remaining holdings are reported as 0 shares, which may reflect a one-time liquidation rather than a trend.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-11, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for McKesson, reported by a director.

Company-level read

Ticker impact

$MCKNeutralLow confidence
Context

McKesson Form 4 shows director Lerman Bradley E sold 301 shares on 2026-08-10 at $892.3250, exiting the position.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 insider transaction, not earnings, guidance, or a corporate action. The article provides sale size and price but no new company-specific operating or regulatory development.

Market effects

None indicated; this is company-specific insider selling.

None indicated.

None indicated.

Counterpoint

The sale could be non-informational (taxes, diversification, or pre-planned liquidity), especially since the filing does not provide a 10b5-1 plan.

Key entities

  • MCK

    McKesson Corporation, the company whose insider transaction is disclosed.

  • Lerman Bradley E

    Director who sold 301 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.